Back to Awarded Treatment Trials
Awarded Trial: 05T-678
Grant ID
05T-678
Illness
Schizophrenia
Primary Drug/Intervention
Cannabidiol
Primary Dosage
200 mg t.i.d.
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Leweke
Sample Size
16
Duration of Study Period for Each Subject
31 days
Outcome Measurements
PANSS, BPRS, CGI, BDIS, Quality of life scale, SAS
Results
Twenty-nine (29) individuals with acute schizophrenia were randomized to cannabidiol 600 mg/d or placebo for 14 days, then crossed over to the other treatment for 14 days. Assessments were done with BPRS, PANSS, CGI, HAM-A, and CDSS. Individuals on cannabidiol showed greater improvement, but it did not achieve statistical significance.
Publication
N/A
Link
N/A
PI Name
Franz-Markus Leweke
Degree
MD
Center
Department of Psychiatry and Psychotherapy
Institution
Klinikum der Unversitaet zu Koeln
Address
Kerpener Str. 62
City or Town
Koeln
State or Province
N/A
Zip or Postal Code
50937
Country
Germany
Email Address
m.leweke@uni.de